Loading...
Profile of secukinumab in the treatment of psoriasis: current perspectives
Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. It is known that this cytokine is elevated in lesions of psoriasis. Interleukins in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus beco...
Na minha lista:
| Udgivet i: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4671779/ https://ncbi.nlm.nih.gov/pubmed/26664127 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S79053 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|